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Infectious hypothesis of Alzheimer disease
Charles E. SeaksID, Donna M. WilcockID*
Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States of America
* donna.wilcock@uky.edu
Alzheimer disease
Alzheimer disease (AD) is the leading cause of dementia worldwide, accounting for almost
70% of all dementia cases, and is one of the fastest growing healthcare price burdens. Patholog-
ically, AD is characterized by the presence of beta amyloid (Aβ) plaques and neurofibrillary
tangles composed of aggregated microtubule associated protein tau. Clinically, AD manifests
as progressive cognitive decline and worsening memory deficits [1]. The traditional hypothesis
on the progression of AD pathologies states that Aβ plaques appear first, causing hyperpho-
sphorylation of tau, leading to tangles and neurodegeneration. However, with the continued
failure of clinical trials aimed at decreasing Aβ plaques, this hypothesis has come under scru-
tiny while alternative hypotheses are being investigated. One of the more controversial emerg-
ing hypotheses is the infectious hypothesis.
The infectious hypothesis
The infectious hypothesis proposes that a pathogen (virus, bacteria, prion, etc.) is the root
cause of AD [2]. The hypothesis is supported by evidence that some pathogens, such as herpes-
viruses and certain bacterial species, are found more commonly in AD patients. There is some
variation within the infectious hypothesis field as to how an infectious pathogen explains the
pathological hallmarks of AD. Direct infection and eventual death of central nervous system
(CNS) cells by pathogens could explain the cognitive deficits and heightened inflammation
found in AD [3]. The relationship between inflammation and the AD hallmarks has long been
recognized, with inflammation hypothesized to cause tissue damage, leading to protein aggre-
gates such as Aβ plaques and tangles, which in turn can lead to more inflammation [4]. This
cascade could be initiated by a number of endogenous and external factors, including micro-
bial pathogens. Alternatively, Aβ and tau may be the products of normal responses to infec-
tion, intended to sequester threats to the CNS [5]. Accumulation of Aβ and tau could then
occur when the generation of the aggregates outpaces clearance by the microglia in the brain, a
process brought about by the natural process of aging [5]. Such an antimicrobial role–centered
model is illustrated in Fig 1. The aggregates themselves have shown to trigger neuroinflamma-
tion as well [6]. Recent findings have highlighted a number of pathogens as potential drivers of
AD, but the family of pathogens most investigated is the herpesviruses [7].
Herpesviruses and potential contributions to Alzheimer disease:
What is currently known?
The herpesviruses are a family of enveloped, double-stranded DNA viruses capable of infecting
a wide range of mammalian species [8]. The worldwide ubiquity of herpesviruses tends to be
high due to their relatively broad tropism, with some species, such as the herpes simplex
viruses, reaching over 80% seroprevalence in humans [7]. Herpes simplex virus 1 (HSV-1) is
the most commonly studied pathogen in the context of AD, primarily due to identification
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years ago of HSV-1 DNA in AD patient brains at autopsy [9,10]. The first of these studies [10]
identified latent virus in both normal and AD brains but postulated that differences in viral
expression and susceptibility might underlie HSV-1 contribution to AD. Itzhaki and col-
leagues [9] then demonstrated that the presence of ApoE4, the strongest genetic risk factor for
AD, and HSV-1 together was a stronger risk factor for the development of AD than either fac-
tor on its own. While a role for HSV-1 has long been suspected in AD, other members of the
herpesviruses have recently been implicated, including cytomegalovirus, Epstein–Barr virus,
and human herpesvirus 6 (HHV6) [11]. Largely, these studies have consisted of screening
patient samples for the presence of these viruses, either through immunoglobulin titers or
direct PCR amplification of viral DNA, and then comparing between AD and normal patients.
More specific work has focused on HHV6’s ability to seed Aβ plaques in vitro and in vivo [12].
HSV-1 establishes latency in the ganglia of the trigeminal nerve, giving it access to the CNS
after initial infection in the peripheral tissue of the lips and mouth [8]. Latency of HSV-1 is
maintained by an RNA transcript known as the latency transcript [13]. This prevents the host
immune system from identifying mature viral proteins and nucleic acids that would trigger an
innate immune response [8]. This latency can be broken by a number of factors, including UV
light, physical damage, hormonal changes, and off-target effects of pharmaceuticals, leading to
a reestablished active infection [13]. The chief clinical indicator of this reactivation is the pres-
ence of the herpetic lesions colloquially known as “cold sores” or “fever blisters.” In a healthy
Fig 1. Conceptual framework of the infectious hypothesis as it relates to beta amyloid plaque deposition. Created with Biorender.com.
https://doi.org/10.1371/journal.ppat.1008596.g001
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individual, the infection remains in the periphery, as the intrinsic immunity of the brain pre-
vents the further propagation of the virus into the CNS [14]. However, in older or immuno-
compromised individuals, this intrinsic immunity is impaired, allowing the virus to spread
into the rest of the brain [15].
The presence of herpesviruses in the CNS may clinically progress in a number of ways. The
most severe, but relatively rare, outcome is an exaggerated immune response leading to herpes
simplex encephalitis [16]. The potentially more relevant course for development of AD is a
subclinical infection resulting in the virus establishing latency in CNS resident cells [17]. From
here, the virus can reactivate periodically, spreading further and establishing more latent popu-
lations. This cycle of active and latent states could also explain the aging nature of AD, with a
certain number of reactivation cycles to reach a viral load level necessary to overwhelm the
response of the brain or cause enough damage to exhibit clinical symptoms [17]. De Chiara
and colleagues demonstrated that recurrent reactivation of HSV-1 in a wild-type mouse model
could produce hallmark AD pathology, accompanied by cognitive deficits, an intriguing result
that supports the hypothesis that reactivation is critical in the connection between herpesvi-
ruses and AD.
Herpesviruses have been implicated in AD through the isolation of viral DNA from AD
patients, as well as through epidemiological data [18]. A relatively recent study utilizing
national insurance information in Taiwan showed that patients showing infection by herpesvi-
ruses were more likely to be diagnosed with multiple forms of dementia, including AD. Specif-
ically, patients infected with HSV-1 had a hazard ratio of 2.564, indicating a 2.56-fold increase
in likelihood of developing dementia [18]. Additionally, they showed that treatment with anti-
herpetic therapeutics, specifically acyclovir, decreased the likelihood of being diagnosed with
those same forms of dementia significantly. Use of any antiherpetics resulted in hazard ratios
well below 1.0, indicating decreasing risk of developing dementia.
Future directions of the infectious hypothesis
There is mounting support and evidence for the infectious hypothesis. At numerous confer-
ences on AD, the number of abstracts examining the connection between pathogens and the
development of AD has increased in recent years, and dedicated sessions and panels have
begun to arise. Considerable work is still needed, however, to more convincingly connect AD
and infectious agents. First and foremost, important questions on the relationship between
established risk factors of AD and pathogen infections remain to be addressed. There has
always been the lingering question of how pathogens ubiquitous in much of the population are
causing a disease in only a subset of that population. The answer to this selective vulnerability
likely lies within the infectious hypothesis’s interactions with other theories and risk factors.
Could clearance of Aβ and tau, used to stop HSV-1 spread, be impaired due to changes in vas-
cular health? Could breakdown of the blood–brain barrier with age be providing new sites of
entry for other pathogens? There is therefore a need for increased research in the AD field
with respect to infectious pathogens. Many of the well-known AD risk genes, such as apolipo-
protein-E, are related to immunity or, in some cases, life cycle of the pathogens [11]. A review
by Dr. Steven Harris and Dr. Elizabeth Harris discussing what we already know about these
interactions is recommended to any interested readers (see [13]). Instead of viewing the infec-
tious hypothesis as a standalone entity, it should be investigated through the lens of interactiv-
ity with other components of the disease. Such holistic, inclusive approaches are a natural
progression toward a larger hypothesis, a process that the Aβ hypothesis has had to undergo,
which then leads to another question: why has the process been so slow for the infectious
hypothesis?
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The Alzheimer disease field and infectious hypothesis
The answer likely stems from the composition of the AD field. Though expanding and diversi-
fying, most AD researchers are not microbiologists or virologists. Typically, they are neurosci-
entists, biochemists, neuropathologists, neuropsychologists, and pharmacologists. There is a
distinct lack of overlap between the disciplines that is sometimes hard to bridge in terms of
forming collaborations or productive dialogue. The number of individuals who work on AD
and identify as a microbiologist or virologist is extremely small.
The longstanding support for Aβ research is overwhelming, despite high failure rates for
therapeutics centered on Aβ modulation [19]. NIH funding for AD research as of this article’s
writing sits at $2.3 billion, a funding level reflective of the imminent health concern AD repre-
sents. Of the NIH AD funding, a negligible amount is used to investigate pathogens in AD
[20]. However, the recent announcement of special interest by the National Institute on Aging
(NIA) for grants examining a potential connection between pathogens and AD represents an
important step in increased funding in this area (Notice #: NOT-AG-19-012).
Despite the challenges the infectious hypothesis faces, there are reasons to be hopeful for
further research in this area. Recent studies have contributed significant evidence to the infec-
tious hypothesis and have received public attention [12,21]. Eimer and colleagues [12], as pre-
viously mentioned, demonstrated the ability of herpesviruses to seed Aβ plaques and showed
that these plaques act in an antiviral manner. This provided a clear mechanistic connection
between herpesviruses and the development of pathology. Readhead and colleagues [21]
showed significant overlap of affected pathways in HHV6 infection and AD, specifically
related to amyloid precursor protein (APP) processing to the Aβ peptide, forming oligomers,
and ultimately amyloid plaques. This connection in pathways strongly supports the theory that
herpesviruses contribute to AD and fits within the antimicrobial Aβ theory, with the presence
of herpesviruses triggering up-regulation of APP metabolism.
Organizations related to the infectious hypothesis have been growing as well, including the
Alzheimer’s Germ Quest, Inc, founded by Dr. Leslie Norins to provide a challenge award for
research identifying a causative pathogen of AD. Representatives from the Human Herpesvi-
rus 6 Foundation have been offering assistance in the form of reagents and funding for groups
interested in pursuing the connection of HHV6 to AD. A petition for increased allocations of
funds for infectious AD–related research has also been started, and funding opportunities,
such as those provided by the NIA, will provide opportunities for further research. Ultimately,
the opportunity for meaningful infectious hypothesis research has never been better. Alterna-
tive hypotheses of AD are being considered more openly than at any point in the past, given
trial failures, and longtime researchers in the field have been fighting for opportunities that are
now becoming a reality.
The next stage in infectious hypothesis research is difficult to predict. Recent work has
highlighted the connection between HSV-1 reactivation and AD pathology [7]. Clinical trials
are under way by researchers that are looking at the use of antivirals in treating AD (Clincial-
Trials.gov Identifier: NCT03282916). Gingivitis and chlamydia have also been recently
implicated in AD, giving credence to the idea that Aβ plaques are a broad antimicrobial pep-
tide [22,23]. Determining common characteristics of pathogens that contribute to AD would
be a step forward, as it would allow investigators to identify other potential pathogens and
winnow the field of potentially relevant interactions with risk factors. There are a large num-
ber of identified risk factors for AD, and establishing how pathogens may be interacting with
them is an important issue. Ultimately, these questions require answers that will come
slowly; however, increased attention, collaboration, and funding will be necessary to answer
them.
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For those with greater interest in specific aspects of the infectious hypothesis, we would
direct you to more comprehensive reviews written by Dr. Ruth Itzhaki, who frequently pub-
lishes scientific reviews on the topic.
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